CORE--BONE HISTOMORPHOMETRY

该组织形态测定核心已成为我们 SCOR 计划的组成部分 自 1987 年成立以来。在本申请中，核心提供 对五个项目中的四个以及对 3D结构评估的可行性项目。在整个过程中 五年内，核心将准备和分析超过 600 只大鼠和小鼠 标本和 200 份人体活组织检查。将采用骨组织形态计量学 表征缺乏该基因的转基因小鼠的骨骼表型 p53抑癌基因。骨组织形态计量学将得到广泛应用 探讨PTH的合成代谢作用及其相互作用的机制 膳食钙缺乏和 PT 给药之间的关系。骨 组织形态计量学将用于表征细胞和 甲状旁腺切除术对轻度绝经后妇女的结构影响 原发性甲状旁腺功能亢进症。骨组织形态计量学将用于探索 患者体内 PTH 初始强烈合成代谢作用的机制 患有骨质疏松症。通过微型 MRI 评估的结构变量将 与松质和松质的组织形态计量变量相关 皮质骨结构。该核心将采用最先进的技术 并将拥有超过 15 年的样品分析经验 和数据的解释。

This histomorphometry core has been in integral part of our SCOR program since its inception in 1987. In the present application, the core provides histomorphometric support for four of the five projects and for the feasibility project on assessment of 3-d structure. Over the course of the five years the core will prepare and analyze over 600 rat and mouse specimens and 200 human biopsies. Bone histomorphometry will be employed to characterize the skeletal phenotype of transgenic mice which lack the p53 tumor suppressor gene. Bone histomorphometry will be used extensively to explore the mechanism of the anabolic action of PTH and interaction between dietary calcium deficiency and PT administration. Bone histomorphometry will be employed to characterize the cellular and structural effects of parathyroidectomy in postmenopausal women with mild primary hyperparathyroidism. Bone histomorphometry will be used to explore the mechanism of the initial intense anabolic action of PTH in patients with osteoporosis. Structural variables, assessed by Micro-MRI, will be correlated with histomorphometric variables of both cancellous and cortical bone structure. This core will employ state of the art technology and will bring over 15 years of experience to the analysis of the samples and interpretation of the data.